Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction.

Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemerrle M, Gharpure KM, Rupaimoole R, Previs R, Wu SY, Pradeep S, Xu X, Dong Han H, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong ST, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, diBiasi M, Sood AK.

Cancer Res. 2018 Apr 16. pii: canres.1701.2016. doi: 10.1158/0008-5472.CAN-16-1701. [Epub ahead of print]

PMID:
29661830
2.

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK.

Clin Cancer Res. 2017 Nov 15;23(22):7034-7046. doi: 10.1158/1078-0432.CCR-17-0647. Epub 2017 Aug 29.

PMID:
28855350
3.

Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.

Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw296.

PMID:
28376174
4.

SSRI use and clinical outcomes in epithelial ovarian cancer.

Christensen DK, Armaiz-Pena GN, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D, Thaker PH, Ahmed A, Penedo FJ, DeGeest K, Mendez L, Domann F, Sood AK, Lutgendorf SK.

Oncotarget. 2016 May 31;7(22):33179-91. doi: 10.18632/oncotarget.8891.

5.

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.

Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

J Clin Invest. 2016 May 2;126(5):1885-96. doi: 10.1172/JCI85086. Epub 2016 Apr 11.

6.

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.

Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK.

Nat Commun. 2016 Apr 4;7:11169. doi: 10.1038/ncomms11169.

7.

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.

Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK.

Oncogene. 2016 Aug 18;35(33):4312-20. doi: 10.1038/onc.2015.492. Epub 2016 Jan 4.

8.

Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.

Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK.

Cell Rep. 2015 Dec 22;13(11):2395-2402. doi: 10.1016/j.celrep.2015.11.047. Epub 2015 Dec 10.

9.

Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.

Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram P, Sehgal V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK.

Clin Cancer Res. 2016 Apr 1;22(7):1713-24. doi: 10.1158/1078-0432.CCR-15-1275. Epub 2015 Nov 18.

10.

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.

Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK.

Mol Cancer Ther. 2015 Dec;14(12):2677-86. doi: 10.1158/1535-7163.MCT-14-0630. Epub 2015 Oct 29.

11.

Erythropoietin Stimulates Tumor Growth via EphB4.

Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK.

Cancer Cell. 2015 Nov 9;28(5):610-622. doi: 10.1016/j.ccell.2015.09.008. Epub 2015 Oct 17.

12.

Targeting c-MYC in Platinum-Resistant Ovarian Cancer.

Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE.

Mol Cancer Ther. 2015 Oct;14(10):2260-9. doi: 10.1158/1535-7163.MCT-14-0801. Epub 2015 Jul 30.

13.

PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.

Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK.

Mol Cancer Ther. 2015 Jun;14(6):1466-1475. doi: 10.1158/1535-7163.MCT-14-1077. Epub 2015 Apr 1.

14.

Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.

Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G.

Oncotarget. 2015 Feb 28;6(6):4266-73.

15.

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK.

Cancer Metastasis Rev. 2015 Mar;34(1):19-40. doi: 10.1007/s10555-014-9538-9. Review.

16.

Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.

Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK.

Nat Commun. 2014 Oct 29;5:5202. doi: 10.1038/ncomms6202.

17.

Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.

Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC.

Nat Commun. 2014 Oct 3;5:5092. doi: 10.1038/ncomms6092.

18.

Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.

Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G.

Mol Cancer Ther. 2014 Nov;13(11):2583-94. doi: 10.1158/1535-7163.MCT-14-0028. Epub 2014 Sep 5.

19.

Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK.

Cancer Biol Ther. 2014 Jul;15(7):919-29. doi: 10.4161/cbt.28882. Epub 2014 Apr 23.

20.

Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.

Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK.

Mol Cancer Ther. 2014 Jul;13(7):1750-7. doi: 10.1158/1535-7163.MCT-13-0930. Epub 2014 Apr 22.

21.

2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK.

Nat Commun. 2014 Mar 12;5:3459. doi: 10.1038/ncomms4459.

22.

Monocyte subpopulations in angiogenesis.

Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK.

Cancer Res. 2014 Mar 1;74(5):1287-93. doi: 10.1158/0008-5472.CAN-13-2825. Epub 2014 Feb 20. Review.

23.

Src activation by β-adrenoreceptors is a key switch for tumour metastasis.

Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK.

Nat Commun. 2013;4:1403. doi: 10.1038/ncomms2413. Erratum in: Nat Commun. 2013;4:1932. Shazhad, Mian M K [corrected to Shahzad, Mian M K].

24.

Why stress is BAD for cancer patients.

Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK.

J Clin Invest. 2013 Feb;123(2):558-60. doi: 10.1172/JCI67887. Epub 2013 Jan 25.

25.

Neuroendocrine influences on cancer progression.

Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK.

Brain Behav Immun. 2013 Mar;30 Suppl:S19-25. doi: 10.1016/j.bbi.2012.06.005. Epub 2012 Jun 21. Review.

26.

Paraneoplastic thrombocytosis in ovarian cancer.

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

N Engl J Med. 2012 Feb 16;366(7):610-8. doi: 10.1056/NEJMoa1110352. Erratum in: N Engl J Med. 2012 Nov;367(18):1768. Lamkin, Donald [added].

27.

Targeting SRC in mucinous ovarian carcinoma.

Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK.

Clin Cancer Res. 2011 Aug 15;17(16):5367-78. doi: 10.1158/1078-0432.CCR-10-3176. Epub 2011 Jul 7.

28.

Functional roles of Src and Fgr in ovarian carcinoma.

Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2011 Apr 1;17(7):1713-21. doi: 10.1158/1078-0432.CCR-10-2081. Epub 2011 Feb 7.

29.

Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.

Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK.

J Biol Chem. 2010 Nov 12;285(46):35462-70. doi: 10.1074/jbc.M110.109579. Epub 2010 Sep 8.

30.

Regulation of tumor angiogenesis by EZH2.

Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK.

Cancer Cell. 2010 Aug 9;18(2):185-97. doi: 10.1016/j.ccr.2010.06.016.

31.

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.

Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK.

J Clin Invest. 2010 May;120(5):1515-23. doi: 10.1172/JCI40802. Epub 2010 Apr 12.

32.

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Feb;9(3):176-82. Epub 2010 Feb 16.

33.

Therapeutic Targeting of ATP7B in Ovarian Carcinoma.

Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK.

Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26.

34.

Estrous cycle modulates ovarian carcinoma growth.

Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK.

Clin Cancer Res. 2009 May 1;15(9):2971-8. doi: 10.1158/1078-0432.CCR-08-2525. Epub 2009 Apr 21.

35.

Functional significance of VEGFR-2 on ovarian cancer cells.

Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK.

Int J Cancer. 2009 Mar 1;124(5):1045-53. doi: 10.1002/ijc.24028.

36.

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK.

Clin Cancer Res. 2008 Sep 1;14(17):5437-46. doi: 10.1158/1078-0432.CCR-07-4922.

37.

Neuroendocrine modulation of cancer progression.

Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK.

Brain Behav Immun. 2009 Jan;23(1):10-5. doi: 10.1016/j.bbi.2008.06.007. Epub 2008 Jun 27. Review.

38.

Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.

Landen CN Jr, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK.

Cancer Res. 2007 Nov 1;67(21):10389-96.

39.

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.

Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK.

Clin Cancer Res. 2007 Jun 1;13(11):3423-30.

Supplemental Content

Loading ...
Support Center